E Missov1, J Mair. 1. Department of Cardiology and INSERM U-390, University Hospital of Montpellier, France. missov@medicine.ucsf.edu
Abstract
BACKGROUND: The major structural characteristic of congestive heart failure is myocardial cell death. The aim of our study was to determine whether the level of cardiac troponin T, a protein specific for cardiac necrosis, was increased in patients with congestive heart failure. METHODS AND RESULTS: Plasma samples were obtained from 33 patients and 47 healthy control subjects. Quantitative determination of cardiac troponin T was achieved with a second-generation enzyme immunoassay without cross-reactivity with the skeletal muscle troponin T. The mean circulating level of cardiac troponin T was 0.140 +/- 0.439 ng/mL in patients with heart failure and 0.0002 +/- 0.001 ng/mL in the healthy controls (P =. 0001). To evaluate the relation between structural degradation and functional impairment, patients in heart failure were categorized according to their radionuclide left ventricular ejection fraction (LVEF). In the 23 patients with LVEF </=45%, cardiac troponin T was 0.163 +/- 0.50 ng/mL, a level significantly higher than that in patients with LVEF >45% (P =.04). There was also a negative correlation between cardiac troponin T and LVEF (R = -0.41, P =.01). CONCLUSIONS: These data show that cardiac troponin T is increased in patients with congestive heart failure and that the level parallels the severity of the disease. We conclude that cardiac troponin T is a suitable candidate-marker molecule to monitor congestive heart failure from a structural perspective.
BACKGROUND: The major structural characteristic of congestive heart failure is myocardial cell death. The aim of our study was to determine whether the level of cardiac troponin T, a protein specific for cardiac necrosis, was increased in patients with congestive heart failure. METHODS AND RESULTS: Plasma samples were obtained from 33 patients and 47 healthy control subjects. Quantitative determination of cardiac troponin T was achieved with a second-generation enzyme immunoassay without cross-reactivity with the skeletal muscle troponin T. The mean circulating level of cardiac troponin T was 0.140 +/- 0.439 ng/mL in patients with heart failure and 0.0002 +/- 0.001 ng/mL in the healthy controls (P =. 0001). To evaluate the relation between structural degradation and functional impairment, patients in heart failure were categorized according to their radionuclide left ventricular ejection fraction (LVEF). In the 23 patients with LVEF </=45%, cardiac troponin T was 0.163 +/- 0.50 ng/mL, a level significantly higher than that in patients with LVEF >45% (P =.04). There was also a negative correlation between cardiac troponin T and LVEF (R = -0.41, P =.01). CONCLUSIONS: These data show that cardiac troponin T is increased in patients with congestive heart failure and that the level parallels the severity of the disease. We conclude that cardiac troponin T is a suitable candidate-marker molecule to monitor congestive heart failure from a structural perspective.
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Gregor Lindner; Carmen Andrea Pfortmueller; Christian Tasso Braun; Aristomenis Konstantinos Exadaktylos Journal: Intern Emerg Med Date: 2013-12-11 Impact factor: 3.397